文献速递前列腺增生与排尿功能障碍

多中心前瞻性假对照试验评估生理性闭环可穿戴胫神经调节系统治疗膀胱过度活动症

A Multicenter Prospective Sham-controlled Trial Evaluating a Physiologic Closed-loop Wearable Tibial Neuromodulation System for Overactive Bladder.
PubMed 文献 · Urology · 2024-09-17

这项多中心、前瞻性、随机、双盲、假对照试验纳入125例成人膀胱过度活动症(OAB)患者,按1:1随机接受Vivally系统活性治疗或假治疗。改良意向治疗人群(n=107)中,活性治疗组应答率83.6%显著高于假治疗组57.7%(P=.032),无严重不良事件。

要点

  • 活性治疗组应答率83.6% vs 假治疗组57.7%,差异有统计学意义(P=.032)。
  • 系统安全性良好,无严重不良事件报告。
  • 患者对设备和移动应用的满意度高,90/92(97.8%)报告中度至极度满意。

核心结论

  • Vivally系统较假治疗显著改善OAB症状,表现出高应答率和良好的安全性。
  • 生理性闭环神经调节与行为追踪应用相结合,可能为OAB管理提供有效且用户友好的选择。

研究设计与样本

  • 多中心、前瞻性、随机、双盲、假对照试验,纳入125例成人OAB受试者,按1:1随机接受Vivally系统活性治疗或假治疗。
  • 允许患者继续稳定的伴随OAB药物治疗,并在整个研究期间保持方案一致。
  • 主要疗效终点为应答率,定义为每日急迫性漏尿较基线减少≥50%或每日排尿次数较基线减少≥30%(基于电子排尿日记)。

主要发现

  • 改良意向治疗人群(n=107)中,活性治疗组应答率为83.6%,假治疗组为57.7%,差异有统计学意义(P=.032)。
  • 系统安全性良好,无严重不良事件。
  • 患者对设备和移动应用的满意度高,90/92(97.8%)报告中度至极度满意。
  • 活性治疗组和假治疗组的治疗依从性均高于92%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness and safety of a home-based, physiologic closed-loop wearable tibial neuromodulation system in comparison to a sham control for the treatment of overactive bladder (OAB). METHODS: This multicenter, prospective, randomized, double-blind, sham-controlled trial included 125 adult subjects with OAB who were randomized 1:1 to receive either active therapy with the Vivally System or sham therapy. Patients were allowed to continue concomitant OAB medications if therapy was stable and the remained on a consistent regimen throughout the study. The primary efficacy endpoint was a responder rate, defined as ≥50% reduction in daily urgency leaks or a ≥30% reduction in daily voids from baseline recorded on an electronic voiding diary. Safety was evaluated through adverse event (AE) reporting and patient satisfaction with the system was recorded. RESULTS: In the modified Intent-to-Treat (mITT) population (n = 107), the responder rate was significantly higher in the active therapy arm (83.6%) compared to the sham arm (57.7%; P = .032). The system demonstrated a favorable safety profile with no serious AE. Patient satisfaction with the device and mobile application was high with 90/92 (97.8%) reporting they were moderately to extremely satisfied and therapy compliance was above 92% for both therapy and sham groups. CONCLUSION: The Vivally System showed significant improvement in OAB symptoms compared to sham therapy, demonstrating a high responder rate and excellent safety profile. The combination of physiologic closed-loop neuromodulation and a behavior-tracking application may offer an effective and user-friendly option for OAB management.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Goudelocke C, Dhir R, Shapiro E, et al. A Multicenter Prospective Sham-controlled Trial Evaluating a Physiologic Closed-loop Wearable Tibial Neuromodulation System for Overactive Bladder. Urology. 2024. PMID: 39299396. doi:10.1016/j.urology.2024.09.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。